EUCTR2020-005643-22-ES进行中（未招募）1 期
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 546
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible to participate in this OLE study, participants must meet all the following criteria:
- •1. Completed 30 months of the blinded study treatment in Study AG10-301 and the Study AG10-301 Month 30 visit including assessments and procedures.
- •2. Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- •3. Female participants of childbearing potential who engage in heterosexual intercourse must agree to use a highly effective method of contraception beginning with enrollment and continuing for 30 days after the last dose of acoramidis. Female participants using oral contraceptives must agree to use an additional birth control method. While not considered highly effective, a double-barrier method is acceptable. A male participant who is sexually active with a female of childbearing potential and has not had a vasectomy must agree to use a double-barrier method of birth control.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 11
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 535
排除标准
- •Participants who meet any of the following criteria at the Day 1 visit will not be eligible to participate in the study:
- •1. Has hemodynamic instability, that in the judgment of the Investigator, would pose too great a risk for participation in the study.
- •2. Has had a heart and/or liver transplant within the year prior to Day 1.
- •3. Has had implantation of a cardiac mechanical assist device (CMAD).
- •4. Has confirmed diagnosis of light-chain (AL) amyloidosis at any time during Study AG10-301.
- •5. Is on dialysis or has a degree of renal impairment that in the opinion of the Investigator might jeopardize the participant’s safety, increase their risk from participation, or interfere with the study.
- •6. Known hypersensitivity to acoramidis, its metabolites, or formulation excipients.
- •7. At the end of Study AG10-301 or at Day 1 of Study AG10-304 (or any time during the study), participant is on prohibited medication.
- •8. Females who are pregnant or breastfeeding. A negative urine pregnancy test at the Day 1 visit and at each study visit are required for female participants of childbearing potential.
- •9. In the judgment of the Investigator or Medical Monitor, has any clinically important ongoing medical condition or laboratory abnormality or condition that might jeopardize the participant’s safety, increase their risk from participation, or interfere with the study.
- •10. Participation in another interventional clinical trial (with the exception of Study AG10-301) within 30 days prior to dosing. Participation in observational and/or registry studies should be discussed with the Medical Monitor.
- •11. Has any condition that in the opinion of the Investigator or Medical Monitor would preclude compliance with the study protocol such as a history of substance abuse, alcoholism, or a psychiatric condition.
研究者
相似试验
尚未招募
3 期
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)10082206NL-OMON53804Eidos Therapeutics, Inc.12
进行中（未招募）
1 期
Extension study and safety monitoring of Acoramidis (AG10) in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)MedDRA version: 20.0Level: LLTClassification code 10002020Term: Amyloid cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersEUCTR2020-005643-22-DKEidos Therapeutics, Inc.546
进行中（未招募）
1 期
Extension study and safety monitoring of Acoramidis (AG10) in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)MedDRA version: 20.0Level: LLTClassification code 10002020Term: Amyloid cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersEUCTR2020-005643-22-IEEidos Therapeutics, Inc.546
进行中（未招募）
1 期
Extension study and safety monitoring of Acoramidis (AG10) in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)MedDRA version: 20.0Level: LLTClassification code 10002020Term: Amyloid cardiomyopathySystem Organ Class: 100000004849EUCTR2020-005643-22-ITEidos Therapeutics, Inc546
已完成
3 期
Safety study Of Ulcerative Colitis Patients who participated in other Etrolizumab studyCTRI/2017/04/008364F HoffmannLa Roche Ltd